keyword
https://read.qxmd.com/read/38630199/population-pharmacokinetics-of-adalimumab-in-juvenile-idiopathic-arthritis-patients-a-retrospective-cohort-study-using-clinical-care-data
#1
JOURNAL ARTICLE
Amara Nassar-Sheikh Rashid, Femke Hooijberg, Sandy C Bergkamp, Mariken P Gruppen, Taco W Kuijpers, Mike Nurmohamed, Theo Rispens, Gertjan Wolbink, J Merlijn van den Berg, Dieneke Schonenberg-Meinema, Ron A A Mathôt
BACKGROUND AND OBJECTIVE: Juvenile idiopathic arthritis (JIA) is a chronic autoimmune disorder that primarily affects the joints in children. Notably, it is known to co-occur with uveitis. Adalimumab, a monoclonal anti-TNF antibody, is effective in treating both conditions. A deeper understanding of the pharmacokinetics (PK) of adalimumab in JIA is crucial to advance in more personalized treatment approaches. The objective of this study is to evaluate the population PK profile of adalimumab in JIA and to explain causes for its variability...
April 17, 2024: Paediatric Drugs
https://read.qxmd.com/read/38627763/impact-of-attaining-aggressive-vs-conservative-pk-pd-target-on-the-clinical-efficacy-of-beta-lactams-for-the-treatment-of-gram-negative-infections-in-the-critically-ill-patients-a-systematic-review-and-meta-analysis
#2
JOURNAL ARTICLE
Milo Gatti, Pier Giorgio Cojutti, Federico Pea
BACKGROUND: To perform a systematic review with meta-analysis with the dual intent of assessing the impact of attaining aggressive vs. conservative beta-lactams PK/PD target on the clinical efficacy for treating Gram-negative infections in critical patients, and of identifying predictive factors of failure in attaining aggressive PK/PD targets. METHODS: Two authors independently searched PubMed-MEDLINE and Scopus database from inception to 23rd December 2023, to retrieve studies comparing the impact of attaining aggressive vs...
April 16, 2024: Critical Care: the Official Journal of the Critical Care Forum
https://read.qxmd.com/read/38626241/amoxicillin-clavulanate-breakpoints-against-enterobacterales-rationale-for-revision-by-the-clinical-and-laboratory-standards-institute
#3
JOURNAL ARTICLE
Navaneeth Narayanan, Amy J Mathers, Eric Wenzler, Nicholas M Moore, Christian G Giske, Rodrigo E Mendes, Paul H Edelstein
Amoxicillin-clavulanate (AMC) is among the most frequently prescribed antibiotics globally. It has broad antibacterial activity against gram-positive, gram-negative, and anaerobic bacteria, and has been utilized to treat infections caused by a broad range of pathogens. AMC breakpoints against Enterobacterales were initially set in the 1980s but since then increases in antibiotic resistance, advances in pharmacokinetic (PK)/pharmacodynamic (PD) analyses, and publication of additional clinical data prompted a reassessment by the Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing...
April 16, 2024: Clinical Infectious Diseases
https://read.qxmd.com/read/38625397/molecular-dynamic-investigation-for-roco4-kinase-inhibitor-as-treatment-options-for-parkinsonism
#4
JOURNAL ARTICLE
Kankana Dutta, Lokesh Ravi
CONTEXT: Parkinson's disease is a neurodegenerative condition characterized by the degeneration of dopaminergic neurons, resulting in motor disabilities such as rigidity, bradykinesia, postural instability, and resting tremors. While the exact cause of Parkinson's remains uncertain, both familial and sporadic forms are often associated with the G2019S mutation found in the kinase domain of LRRK2. Roco4 is an analogue of LRRK2 protein in Dictyostelium discoideum which is an established model organism to investigate LRRK2 inhibitors...
April 16, 2024: Journal of Molecular Modeling
https://read.qxmd.com/read/38623974/preclinical-pharmacokinetics-and-pharmacology-study-of-rc98-a-programmed-cell-death-ligand-1-monoclonal-antibody-in-cynomolgus-monkeys
#5
JOURNAL ARTICLE
Ling Wang, Qiaoning Li, Chenglian Deng, Zhihao Liu, Fang Wang, Shenjun Li, Lihou Dong, Jing Jiang
INTRODUCTION: RC98 is the monoclonal antibody against Programmed Cell Death Ligand 1 (PD-L1). Relevant reports have confirmed that the influence of PD-L1 expressed by tumor cells on antitumor CD8+ T cell responses is well characterized, but the impact of PD-L1 expressed by immune cells has not been well defined. OBJECTIVE: This study aimed to design a Pharmacokinetics/Pharmacology (PK/PD) study of RC98 in normal cynomolgus monkeys to research the effect on the immune system...
April 15, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38621948/-effects-of-tetramethylpyrazine-on-pharmacokinetics-in-plasma-and-brain-dialysate-and-neuropathic-pain-in-rat-model-of-spared-sciatic-nerve-injury
#6
JOURNAL ARTICLE
Zhi Chen, Dan-Dan DU, Ya Gao, Jun-Miao Chen, Cui-Ping Wei, Xiao-Gang Weng, Jian Sun, Xin-Yuan Wang, Zhi-Guo Wang, Mei-Yu Zhang
This study aims to explore the effects of tetramethylpyrazine(TMP) on pharmacokinetics in plasma and brain dialysate and neuropathic pain in the rat model of partial sciatic nerve injury(SNI), and to investigate the correlation between the analgesic effect of TMP and its concentrations in the plasma and brain dialysate. Male SD rats were randomized into Sham, SNI, and SNI+TMP groups. Mechanical stimulation with von frey filaments and cold spray method were employed to evaluate the mechanical sensitivity and cold sensitivity of rats...
March 2024: Zhongguo Zhong Yao za Zhi, Zhongguo Zhongyao Zazhi, China Journal of Chinese Materia Medica
https://read.qxmd.com/read/38621947/-mechanism-of-fushen-granules-treat-peritoneal-dialysis-related-peritonitis-by-regulating-tlr4-nf-%C3%AE%C2%BAb-pathway-based-on-network-pharmacology-and-animal-experiments
#7
JOURNAL ARTICLE
Hai-Tao Xing, Feng-Mei Ding, Jia-Qi Li, Qian-Yi Zhou, Hong-Tao Yang
Network pharmacology was employed to probe into the mechanism of Fushen Granules in treating peritoneal dialysis-rela-ted peritonitis(PDRP) in rats. The main active components of Fushen Granules were searched against the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, and their targets were predicted. PDRP-related targets were retrieved from DisGeNET and other databases. The common targets shared by the drug and the disease were identified by the online tool, and protein-protein interaction(PPI) network of the common targets...
March 2024: Zhongguo Zhong Yao za Zhi, Zhongguo Zhongyao Zazhi, China Journal of Chinese Materia Medica
https://read.qxmd.com/read/38621565/functional-modification-of-recombinant-brain-derived-neurotrophic-factor-and-its-protective-effect-against-neurotoxicity
#8
JOURNAL ARTICLE
Chang Liu, Qi Yan, Xuying Ding, Meijun Zhao, Chen Chen, Qian Zheng, Huiying Yang, Yining Xie
Brain-derived neurotrophic factor (BDNF) is a neurotrophic protein that promotes neuronal survival, increases neurotransmitter synthesis, and has potential therapeutic effects in neurodegenerative and psychiatric diseases, but its drug development has been limited by the fact that recombinant proteins of BDNF are unstable and do not penetrate the blood-brain barrier (BBB). In this study, we fused a TAT membrane-penetrating peptide with BDNF to express a recombinant protein (TBDNF), which was then PEG-modified to P-TBDNF...
April 13, 2024: International Journal of Biological Macromolecules
https://read.qxmd.com/read/38621236/leucine-rich-repeat-kinases
#9
REVIEW
Dario R Alessi, Suzanne R Pfeffer
Activating mutations in leucine-rich repeat kinase 2 (LRRK2) represent the most common cause of monogenic Parkinson's disease. LRRK2 is a large multidomain protein kinase that phosphorylates a specific subset of the ∼65 human Rab GTPases, which are master regulators of the secretory and endocytic pathways. After phosphorylation by LRRK2, Rabs lose the capacity to bind cognate effector proteins and guanine nucleotide exchange factors. Moreover, the phosphorylated Rabs cannot interact with their cognate prenyl-binding retrieval proteins (also known as guanine nucleotide dissociation inhibitors) and, thus, they become trapped on membrane surfaces...
April 15, 2024: Annual Review of Biochemistry
https://read.qxmd.com/read/38619318/discovery-of-a-pocket-network-on-the-domain-5-of-the-trkb-receptor-a-potential-new-target-in-the-quest-for-the-new-ligands
#10
JOURNAL ARTICLE
Mirjana Antonijevic, Jana Sopkova-de Oliveira Santos, Patrick Dallemagne, Christophe Rochais
The important role that the neurotrophin tyrosine kinase receptor - TrkB has in the pathogenesis of several neurodegenerative conditions such are Alzheimer's disease, Parkinson's disease, Huntington's disease, has been well described. This shouldn't be a surprise, since in the physiological conditions, once activated by brain-derived neurotrophic factor (BDNF) and neurotrophin-4/5 (NT-4/5), the TrkB receptor promotes neuronal survival, differentiation and synaptic function. Considering that the natural ligands for TrkB receptor are large proteins, it is a challenge to discover small molecule capable to mimic their effects...
April 15, 2024: Molecular Informatics
https://read.qxmd.com/read/38619005/characterization-of-structural-biochemical-pharmacokinetic-and-pharmacodynamic-properties-of-the-lsd1-inhibitor-bomedemstat-in-preclinical-models
#11
JOURNAL ARTICLE
Sumer Jasmine, Adel Mandl, Timothy E G Krueger, Susan L Dalrymple, Lizamma Antony, Jennifer Dias, Cassandra A Celatka, Amy E Tapper, Maria Kleppe, Mayuko Kanayama, Yuezhou Jing, Valentina Speranzini, Yuzhuo Z Wang, Jun Luo, Bruce J Trock, Samuel R Denmeade, Michael A Carducci, Andrea Mattevi, Hugh Y Rienhoff, John T Isaacs, W Nathaniel Brennen
INTRODUCTION: Lysine-specific demethylase 1 (LSD1) is emerging as a critical mediator of tumor progression in metastatic castration-resistant prostate cancer (mCRPC). Neuroendocrine prostate cancer (NEPC) is increasingly recognized as an adaptive mechanism of resistance in mCRPC patients failing androgen receptor axis-targeted therapies. Safe and effective LSD1 inhibitors are necessary to determine antitumor response in prostate cancer models. For this reason, we characterize the LSD1 inhibitor bomedemstat to assess its clinical potential in NEPC as well as other mCRPC pathological subtypes...
April 15, 2024: Prostate
https://read.qxmd.com/read/38618974/the-effect-of-renal-function-on-the-pharmacokinetics-and-pharmacodynamics-of-enavogliflozin-a-potent-and-selective-sodium-glucose-cotransporter-2-inhibitor-in-type-2-diabetes
#12
JOURNAL ARTICLE
Sae Im Jeong, Mu Seong Ban, Jun-Gi Hwang, Min-Kyu Park, Soo Lim, Sejoong Kim, Soon Kil Kwon, Yoonjin Kim, Jae Min Cho, Jae Jin Na, Wan Huh, Jae-Yong Chung
AIMS: To explore the effect of renal function on the pharmacokinetic (PK) and pharmacodynamic (PD) profile and safety of enavogliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes mellitus (T2DM). METHODS: An open-label, two-part clinical trial was conducted in T2DM patients, stratified by renal function: Group 1, normal renal function; Group 2, mild renal impairment (RI); Group 3, moderate RI; and Group 4, severe RI...
April 15, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38618871/sources-of-pharmacokinetic-and-pharmacodynamic-variability-and-clinical-pharmacology-studies-of-antiseizure-medications-in-the-pediatric-population
#13
REVIEW
Patricia D Maglalang, Jiali Wen, Christoph P Hornik, Daniel Gonzalez
Multiple treatment options exist for children with epilepsy, including surgery, dietary therapies, neurostimulation, and antiseizure medications (ASMs). ASMs are the first line of therapy, and more than 30 ASMs have U.S. Food and Drug Administration (FDA) approval for the treatment of various epilepsy and seizure types in children. Given the extensive FDA approval of ASMs in children, it is crucial to consider how the physiological and developmental changes throughout childhood may impact drug disposition. Various sources of pharmacokinetic (PK) variability from different extrinsic and intrinsic factors such as patients' size, age, drug-drug interactions, and drug formulation could result in suboptimal dosing of ASMs...
April 2024: Clinical and Translational Science
https://read.qxmd.com/read/38618630/endoxifen-in-treatment-of-individuals-with-borderline-personality-disorder-with-predominant-impulsivity-a-case-series
#14
Debanjan Banerjee, Rajashree Ray
Endoxifen, a protein kinase C inhibitor, has been approved for use in manic episodes in India. One of the symptom traits that it predominantly targets is impulsivity. Impulsivity can also be a symptom dimension of other mental health conditions, one of which is Borderline Personality Disorder (BPD). Management of BPD is challenging, with limited pharmacological options that are symptom-directed and psychotherapy sessions that are fraught with early dropouts and lack of compliance. Impulsive behaviors represent a major reason for seeking help in BPD, especially with regard to non-suicidal self-injury, substance abuse, high-risk sexual behavior, aggression, etc...
December 22, 2023: Consort Psychiatr
https://read.qxmd.com/read/38617520/a-novel-pd-1-pd-l1-pathway-related-seven-gene-signature-for-the-development-and-validation-of-the-prognosis-prediction-model-for-breast-cancer
#15
JOURNAL ARTICLE
Peng Zhang, Jingjing Yang, Xiaolong Zhong, Heloisa Sobreiro Selistre-de-Araujo, Stergios Boussios, Yongneng Ma, Hua Fang
BACKGROUND: Breast cancer (BC/BRCA) is the most common carcinoma in women. The average 5-year survival rate of BC patients with stage IV disease is 26%. A considerable proportion of patients still do not receive effective therapy. It is an unmet need to identify novel biomarkers for BC patients. Herein, we evaluated whether the programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) status is associated with the clinical outcomes of BC, based on data from The Cancer Genome Atlas (TCGA)...
March 31, 2024: Translational Cancer Research
https://read.qxmd.com/read/38616411/phase-1-placebo-controlled-single-ascending-dose-trial-to-evaluate-the-safety-pharmacokinetics-and-effect-on-altered-states-of-consciousness-of-intranasal-bpl-003-5-methoxy-n-n-dimethyltryptamine-benzoate-in-healthy-participants
#16
JOURNAL ARTICLE
James Jonathan Rucker, Claire Roberts, Mathieu Seynaeve, Allan H Young, Ben Suttle, Takahiro Yamamoto, Anna O Ermakova, Fiona Dunbar, Frank Wiegand
AIMS: To investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BPL-003, a novel intranasal benzoate salt formulation of 5-methoxy- N,N -dimethyltryptamine (5-MeO-DMT), in healthy participants. METHODS: In all, 44 psychedelic-naïve participants enrolled in the double-blind, placebo-controlled single ascending dose study (1-12 mg BPL-003). Concentrations of 5-MeO-DMT and its pharmacologically active metabolite, bufotenine, were determined in plasma and urine...
April 14, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38614108/rab32-ser71arg-in-autosomal-dominant-parkinson-s-disease-linkage-association-and-functional-analyses
#17
JOURNAL ARTICLE
Emil K Gustavsson, Jordan Follett, Joanne Trinh, Sandeep K Barodia, Raquel Real, Zhiyong Liu, Melissa Grant-Peters, Jesse D Fox, Silke Appel-Cresswell, A Jon Stoessl, Alex Rajput, Ali H Rajput, Roland Auer, Russel Tilney, Marc Sturm, Tobias B Haack, Suzanne Lesage, Christelle Tesson, Alexis Brice, Carles Vilariño-Güell, Mina Ryten, Matthew S Goldberg, Andrew B West, Michele T Hu, Huw R Morris, Manu Sharma, Ziv Gan-Or, Bedia Samanci, Pawel Lis, Maria Teresa Periñan, Rim Amouri, Samia Ben Sassi, Faycel Hentati, Francesca Tonelli, Dario R Alessi, Matthew J Farrer
BACKGROUND: Parkinson's disease is a progressive neurodegenerative disorder with multifactorial causes, among which genetic risk factors play a part. The RAB GTPases are regulators and substrates of LRRK2, and variants in the LRRK2 gene are important risk factors for Parkinson's disease. We aimed to explore genetic variability in RAB GTPases within cases of familial Parkinson's disease. METHODS: We did whole-exome sequencing in probands from families in Canada and Tunisia with Parkinson's disease without a genetic cause, who were recruited from the Centre for Applied Neurogenetics (Vancouver, BC, Canada), an international consortium that includes people with Parkinson's disease from 36 sites in 24 countries...
April 10, 2024: Lancet Neurology
https://read.qxmd.com/read/38612661/applications-of-flow-cytometry-in-drug-discovery-and-translational-research
#18
REVIEW
Sumana Ullas, Charles Sinclair
Flow cytometry is a mainstay technique in cell biology research, where it is used for phenotypic analysis of mixed cell populations. Quantitative approaches have unlocked a deeper value of flow cytometry in drug discovery research. As the number of drug modalities and druggable mechanisms increases, there is an increasing drive to identify meaningful biomarkers, evaluate the relationship between pharmacokinetics and pharmacodynamics (PK/PD), and translate these insights into the evaluation of patients enrolled in early clinical trials...
March 29, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38611871/oleoylethanolamide-and-palmitoylethanolamide-enhance-ifn%C3%AE-induced-apoptosis-in-human-neuroblastoma-sh-sy5y-cells
#19
JOURNAL ARTICLE
Chiara Camoglio, Jihane Balla, Paola Fadda, Simona Dedoni
Oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) are endogenous lipids that act as agonists of the peroxisome proliferator-activated receptor α (PPARα). Recently, an interest in the role of these lipids in malignant tumors has emerged. Nevertheless, the effects of OEA and PEA on human neuroblastoma cells are still not documented. Type I interferons (IFNs) are immunomodulatory cytokines endowed with antiviral and anti-proliferative actions and are used in the treatment of various pathologies such as different cancer forms (i...
April 2, 2024: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://read.qxmd.com/read/38609392/early-deficits-in-an-in-vitro-striatal-microcircuit-model-carrying-the-parkinson-s-gba-n370s-mutation
#20
JOURNAL ARTICLE
Quyen B Do, Humaira Noor, Ricardo Marquez-Gomez, Kaitlyn M L Cramb, Bryan Ng, Ajantha Abbey, Naroa Ibarra-Aizpurua, Maria Claudia Caiazza, Parnaz Sharifi, Charmaine Lang, Dayne Beccano-Kelly, Jimena Baleriola, Nora Bengoa-Vergniory, Richard Wade-Martins
Understanding medium spiny neuron (MSN) physiology is essential to understand motor impairments in Parkinson's disease (PD) given the architecture of the basal ganglia. Here, we developed a custom three-chambered microfluidic platform and established a cortico-striato-nigral microcircuit partially recapitulating the striatal presynaptic landscape in vitro using induced pluripotent stem cell (iPSC)-derived neurons. We found that, cortical glutamatergic projections facilitated MSN synaptic activity, and dopaminergic transmission enhanced maturation of MSNs in vitro...
April 12, 2024: NPJ Parkinson's Disease
keyword
keyword
57411
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.